1. Home
  2. RIGL vs VCV Comparison

RIGL vs VCV Comparison

Compare RIGL & VCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • VCV
  • Stock Information
  • Founded
  • RIGL 1996
  • VCV 1993
  • Country
  • RIGL United States
  • VCV United States
  • Employees
  • RIGL N/A
  • VCV N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • VCV Trusts Except Educational Religious and Charitable
  • Sector
  • RIGL Health Care
  • VCV Finance
  • Exchange
  • RIGL Nasdaq
  • VCV Nasdaq
  • Market Cap
  • RIGL 486.4M
  • VCV 534.9M
  • IPO Year
  • RIGL 2000
  • VCV N/A
  • Fundamental
  • Price
  • RIGL $20.09
  • VCV $11.07
  • Analyst Decision
  • RIGL Buy
  • VCV
  • Analyst Count
  • RIGL 5
  • VCV 0
  • Target Price
  • RIGL $34.80
  • VCV N/A
  • AVG Volume (30 Days)
  • RIGL 223.6K
  • VCV 107.9K
  • Earning Date
  • RIGL 03-04-2025
  • VCV 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • VCV 4.09%
  • EPS Growth
  • RIGL N/A
  • VCV N/A
  • EPS
  • RIGL 0.22
  • VCV 0.13
  • Revenue
  • RIGL $157,374,000.00
  • VCV N/A
  • Revenue This Year
  • RIGL $51.34
  • VCV N/A
  • Revenue Next Year
  • RIGL $15.75
  • VCV N/A
  • P/E Ratio
  • RIGL $91.32
  • VCV $75.82
  • Revenue Growth
  • RIGL 21.65
  • VCV N/A
  • 52 Week Low
  • RIGL $7.48
  • VCV $8.05
  • 52 Week High
  • RIGL $29.82
  • VCV $10.40
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 45.75
  • VCV 54.00
  • Support Level
  • RIGL $20.00
  • VCV $10.98
  • Resistance Level
  • RIGL $21.93
  • VCV $11.13
  • Average True Range (ATR)
  • RIGL 1.30
  • VCV 0.12
  • MACD
  • RIGL -0.27
  • VCV -0.02
  • Stochastic Oscillator
  • RIGL 2.01
  • VCV 37.78

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About VCV Invesco California Value Municipal Income Trust

Invesco California Value Municipal Income Trust is engaged in the field of financial services. Its objective is to seek to provide common shareholders with a high level of current income exempt from federal and California income taxes, consistent with preservation of capital.

Share on Social Networks: